HDFC Securities' research report on Dabur
Dabur's 2QFY21 saw strong revenue growth, beating our as well as the street's expectations. Domestic val/vol growth was at 20/17% YoY (HSIE 7/10%). Healthcare portfolio clocked stellar 49% growth, led by continued traction for health products. HPC was up by 9% while Food business declined by 4%. Higher rural mix (rural growth was at ~23% YoY) and strong e-commerce growth (up 200% YoY) supported growth. EBITDA margin expanded despite the ramp-up in ASP (up 40% YoY). Company's new launches are increasing essential portfolio as the core portfolio is more discretionary in nature. Dabur's brand positioning (natural and trusted) and the broader portfolio was always exciting, but new energy infused by the CEO (focus on scaling power brands) seems to be a structural change. We increase our EPS for FY21/FY22/FY23 by 4/5/8%.
Outlook
We roll forward our target price to Sep-22E EPS and value Dabur at 42x P/E to derive a target price of Rs 470. However, rich valuation still does not offer the right entry level at CMP. Maintain REDUCE.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.